DOCSLIB.ORG

Wednesday April 10, 2019

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Wednesday April 10, 2019 Wednesday April 10, 2019 11.30 – 12.30 Registration 12.30 – 12.45 Introduction Laurent Kaiser Head of Division of Infectious Diseases, University Hospital Geneva, Faculty of Medicine University of Geneva, Switzerland Henri Bounameaux Dean of the Faculty of Medicine University of Geneva, Switzerland Session I: Arbovirus Emergence in Europe Chairs: Shindo Nahoko (World Health Organization), Pascal Cherpillod (University Hospital Geneva) 12.45 – 12.55 A Case of Autochthonous CCHF Jose Arribas Transmission in Spain Hospital Universitario La Paz, Madrid, Spain 12.55 – 13.15 CCHF in Europe – Lessons from Tom Fletcher Turkey Liverpool School of Tropical Medicine, Liverpool, UK 13.15 – 13.35 Mayaro, Usutu, West Nile - the Jonas Schmidt-Chanasit Next Emerging Arbovirus? Bernhard-Nocht-Institute Hamburg, Germany 13.35 – 13.50 Discussion 13.50 – 14.20 Coffee Break Session II: Yellow Fever Virus – Old Virus, New Challenges Chairs: François Chappuis (Faculty of Medicine University of Geneva and Geneva University Hospitals), Amadou Sall (Institute Pasteur Dakar) 14.20 – 14.30 A Case of Imported Yellow Fever Annelies Zinkernagel in Switzerland University Hospital Zurich, Switzerland 14.30 – 14.50 Severe Yellow Fever – Clinical Ho Yeh Li Experience from Brazil University of Sao Paulo, Brazil 14.50 – 15.10 Epidemiology & Ecology of the Jan Felix Drexler YFV Outbreak – why now? Charité Berlin, Germany 15.10 – 15.25 Discussion 15.25 – 15.50 Break Evening Lectures 15.50 – 16.10 Welcome Note Isabella Eckerle Geneva Centre for Emerging Viral Diseases, Geneva, Switzerland Bertrand Levrat General Director, University Hospital Geneva 16.15 - 16.45 Snakebite: From Research to François Chappuis Public Health Interventions University Hospital Geneva, Switzerland 16.45 -17.15 Crisis Management in Emergency Esperanza Martinez Situations International Committee of the Red Cross, Geneva, Switzerland Social Program 18.00 Guided Tour of the International Red Cross Museum & Apero 1 Thursday April 11, 2019 Session I: Vaccines for Emerging Viruses – the Long and Winding Road to Protection Chairs: Olivia Keiser (Institute of Global Health Geneva), Ana Rita Gonçalves Cabecinhas (University Hospital Geneva) 08.30 – 8.50 The Ups and Downs of Dengue Annelies Wilder-Smith Vaccination Initiative for Vaccine Research, WHO, Geneva, Switzerland 08.50 - 09.10 Evolutionary Dynamics of Colin Russell Influenza Viruses Academic Medical Center of the University of Amsterdam, The Netherlands 09.10 – 9.25 Discussion Session II: Emerging Virus of Global Relevance: Measles, HIV and Enteric Viruses Chairs: Klara Posfay-Barbe (Faculty of Medicine University of Geneva and Geneva University Hospitals), Volker Thiel (University Bern) 09.30 - 09.50 Measles Epidemiology – Sabine Santibanez Drawbacks and Current Robert Koch Institute, Germany Challenges 09.50 – 10.10 HIV Control : Unresolved and Alexandra Calmy Emerging Issues Faculty of Medicine University of Geneva and Geneva University Hospitals, Switzerland 10.10 – 10.30 The Rapidly Evolving World of Marion Koopmans Enteric Viruses Erasmus Medical Centre, Rotterdam, The Netherlands 10.30 – 10.45 Discussion 10.45 – 11.15 Coffee break Session III: Novel Approaches to Tackle Emerging Viruses Chairs: Manuel Schibler (University Hospital Geneva), Noël Tordo (Institute Pasteur Guinea) 11.20 – 11.30 A Mobile Laboratory for Outbreak Rudi Pauwels Situations Praesens Foundation, Belgium 11.30 - 11.50 Precision Global Health – Antoine Flahault Forecasting Outbreaks? Institute of Global Health, Faculty of Medicine University of Geneva, Switzerland 11.50 – 12.05 Discussion Session IV: Ebola - Recent Challenges and New Approaches Chairs: Olivier Engler (Federal Office for Civil Protection Switzerland), Daniel Bausch (London School of Tropical Medicine and Hygiene) 12.10 – 12.20 Ebola in DRC – a clinical point of Pauline Vetter view University Hospital Geneva, Switzerland 12.20 - 12.40 Challenges of the current Ebola Pierre Formenty outbreak in DRC World Health Organisation, Geneva, Switzerland 12.40 – 12.55 Discussion 12.55 - 14.30 Lunch Venue: Foyer, Campus Biotech 2 Session V: Emerging Rodent-borne Viruses: Lassa and Hantaviruses Chairs: Gary Kobinger (University Laval), Stefan Kunz (University Hospital Lausanne) 14.30 – 14.40 A Case of Imported New World Cornelia Staehelin Hantavirus Infection to University Hospital Bern, Switzerland Switzerland 14.40 – 14.50 A Case of Imported Lassa Virus Timo Wolf Case to Germany Goethe University Frankfurt, Germany 14.50 – 15.10 Lassa – Lessons from the Field Daniel Bausch London School of Tropical Medicine & Hygiene, London, UK 15.10 – 15.30 Novel Diagnostics for Lassa Virus Stephan Günther in the Field Bernhard Nocht Institute Hamburg, Germany 15.30 – 15.45 Discussion 15.45 – 16.15 Coffee break Keynote Lectures: Virus Discovery – the Anticipation of the Next Pandemic? Chairs: Antoine Flahault (Institute of Global Health), Isabella Eckerle (University Hospital Geneva) 16.10 - 16.45 Expansion of the RNA Virosphere Edward Holmes University of Sydney, Australia 16.45 - 17.15 Microbial Discovery, Surveillance, W. Ian Lipkin and Diagnostics Columbia University, New York, USA 17.15 – 17.45 PREDICT and the Global Virome Peter Daszak project Ecohealth Alliance, New York, USA 17.45 – 18.15 Anticipation of the next pandemic Plenary Discussion – How can we do better? Social program 19.30 Conference Dinner Restaurant Vieux-Bois Friday April 12, 2019 Session I: Emerging Viruses and the Brain Chairs: Philip Le Mercier (Swiss Institute of Bioinformatics), Samuel Cordey (University Hospital Geneva) 08.30 - 08.50 The South East Asian Marc Lecuit Encephalitis Project Pasteur Institute Paris, France 08.50 – 09.10 Rabies Risk in Europe and Hervé Bourhy Beyond Pasteur Institut Paris, France 09.10 – 09.25 Discussion Session II: Emerging Viruses from Africa Chairs: Pauline Vetter (University Hospital Geneva), Cassandra Kelly (Foundation for Innovative New Diagnostics) 09.30 - 09.50 Imported Monkeypox to the UK Michael Jacobs Royal Free Hospital, London, UK 09.50 – 10.10 Arboviruses in Africa – Lessons Amadou Sall from Senegal Pasteur Institute Dakar, Senegal 3 10.10 – 10.25 Discussion 10.25 – 10.55 Coffee break Session III: Climate Change and the Impact on Emerging Viruses Chairs: Rafael Ruiz de Castañeda (Institute of Global Health Geneva), Micaela Serafini (Médecins Sans Frontières) 11.00 - 11.20 Climate Change and Health in Rainer Sauerborn Poor Countries Institute of Public Health, Heidelberg, Germany 11.20 – 11.40 Rift-Valley-fever Outbreak Assaf Anyamba Assessment by Satellite-based University Space Research Association & NASA, Land Surface Analysis Goddard Space Flight Center, USA 11.40 – 11.55 Discussion Session IV: Febrile Illness – the Clinical Approach Chairs: Jérôme Pugin (Faculty of Medicine University of Geneva and Geneva University Hospitals), Marylyn Addo (University Hospital Hamburg) 11.55 – 12.15 Febrile Illnesses - What if it is not Daniel Paris a Virus? Swiss TPH, Basle, Switzerland Award lecture 12.15 – 12.30 Award Ceremony Laurent Kaiser Faculty of Medicine University of Geneva and Geneva University Hospitals, Switzerland 12.30 – 13.00 Emerging pathogens then and Pierre Rollin, now - Three decades of hunting Formerly Centers for Disease Control and deadly viruses Prevention, Atlanta, USA 13.00-13.30 A Research Journey through Gary Kobinger Emerging Viruses University Laval, Quebec, Canada 13.30 - 13.45 Closing Remarks & Farewell Laurent Kaiser Head of Division of Infectious Diseases, Faculty of Medicine University of Geneva and Geneva University Hospitals Switzerland Isabella Eckerle Geneva Centre for Emerging Viral Diseases, Faculty of Medicine University of Geneva and Geneva University Hospitals, Switzerland 4 .
Load more

Recommended publications
  • An Update Review of Globally Reported SARS-Cov-2 Vaccines in Preclinical and Clinical Stages
    International Immunopharmacology 96 (2021) 107763 Contents lists available at ScienceDirect International Immunopharmacology journal homepage: www.elsevier.com/locate/intimp Review An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages Hamid Motamedi a, Marzie Mahdizade Ari b, Shirin Dashtbin b, Matin Fathollahi a, Hadi Hossainpour a, Amirhoushang Alvandi a,c, Jale Moradi a, Ramin Abiri a,d,* a Department of Microbiology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran b Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran c Medical Technology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran d Fertility and Infertility Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran ARTICLE INFO ABSTRACT Keywords: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the rapidly spreading COVID-19 pandemic COVID-19 in the world. As an effective therapeutic strategy is not introduced yet and the rapid genetic SARS-CoV-2 variations in the virus, there is an emerging necessity to design, evaluate and apply effective new vaccines. An Vaccines acceptable vaccine must elicit both humoral and cellular immune responses, must have the least side effects and the storage and transport systems should be available and affordable for all countries. These vaccines can be classified into different types: inactivated vaccines, live-attenuated virus vaccines, subunit vaccines, virus-like particles (VLPs), nucleic acid-based vaccines (DNA and RNA) and recombinant vector-based vaccines (repli­ cating and non-replicating viral vector). According to the latest update of the WHO report on April 2nd, 2021, at least 85 vaccine candidates were being studied in clinical trial phases and 184 candidate vaccines were being evaluated in pre-clinical stages.
    [Show full text]
  • Pandemic.Pdf.Pdf
    1 PANDEMICS: Past, Present, Future Published in 2021 by the Mahatma Gandhi Institute of Education for Peace and Challenges & Opportunities Sustainable Development, 35 Ferozshah Road, New Delhi 110001, India © UNESCO MGIEP This publication is available in Open Access under the Attribution-ShareAlike Coordinating Lead Authors: 3.0 IGO (CC-BY-SA 3.0 IGO) license (http://creativecommons.org/licenses/ ANANTHA KUMAR DURAIAPPAH by-sa/3.0/ igo/). By using the content of this publication, the users accept to be Director, UNESCO MGIEP bound by the terms of use of the UNESCO Open Access Repository (http:// www.unesco.org/openaccess/terms-use-ccbysa-en). KRITI SINGH Research Officer, UNESCO MGIEP The designations employed and the presentation of material throughout this publication do not imply the expression of any opinion whatsoever on the part of UNESCO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. The ideas and opinions expressed in this publication are those of the authors; they Lead Authors: NANDINI CHATTERJEE SINGH are not necessarily those of UNESCO and do not commit the Organization. Senior Programme Officer, UNESCO MGIEP The publication can be cited as: Duraiappah, A. K., Singh, K., Mochizuki, Y. YOKO MOCHIZUKI (Eds.) (2021). Pandemics: Past, Present and Future Challenges and Opportunities. Head of Policy, UNESCO MGIEP New Delhi. UNESCO MGIEP. SHAHID JAMEEL Coordinating Lead Authors: Director, Trivedi School of Biosciences, Ashoka University Anantha Kumar Duraiappah, Director, UNESCO MGIEP Kriti Singh, Research Officer, UNESCO MGIEP Lead Authors: Nandini Chatterjee Singh, Senior Programme Officer, UNESCO MGIEP Contributing Authors: CHARLES PERRINGS Yoko Mochizuki, Head of Policy, UNESCO MGIEP Global Institute of Sustainability, Arizona State University Shahid Jameel, Director, Trivedi School of Biosciences, Ashoka University W.
    [Show full text]
  • COVIPENDIUM Aug4.Pdf
    COVIPENDIUM Information available to support the development of medical countermeasures and interventions against COVID-19 Cite as: Martine DENIS, Valerie VANDEWEERD, Rein VERBEEKE, Anne LAUDISOIT, Tristan REID, Emma HOBBS, Laure WYNANTS & Diane VAN DER VLIET. (2020). COVIPENDIUM: information available to support the development of medical countermeasures and interventions against COVID-19 (Version 2020-08-04). Transdisciplinary Insights. This document is conceived as a living document, updated on a weekly basis. You can find its latest version at: https://rega.kuleuven.be/if/corona_covid-19. The COVIPENDIUM is based on open-access publications (scientific journals and preprint databases, communications by WHO and OIE, health authorities and companies) in English language. Please note that the present version has not been submitted to any peer-review process. Any comment / addition that can help improve the contents of this review will be most welcome. For navigation through the various sections, please click on the headings of the table of contents and follow the links marked in blue in the document. Authors: Martine Denis, Valerie Vandeweerd, Rein Verbeke, Anne Laudisoit, Tristan Reid, Emma Hobbs, Laure Wynants, Diane Van der Vliet COVIPENDIUM version: 04 AUG 2020 Transdisciplinary Insights - Living Paper | 1 Contents List of abbreviations .......................................................................................................................................................... 9 Introduction ...................................................................................................................................................................
    [Show full text]
  • Iran Hopes to Defeat COVID with Home-Grown Crop of Vaccines
    Q&A Iran hopes to defeat COVID with home-grown crop of vaccines Iran is one of few Middle Eastern nations to transfer money is restricted, it is difficult with the capacity to develop vaccines. It to buy drugs and medicines. And we have has been doing so in earnest: more than the technology to produce vaccines, so why ten are in development, but little is known not use it? To ensure the safety of Iranians, it about them outside Iran. Nature speaks makes sense to develop a variety of vaccines to Kayhan Azadmanesh, head of the using different research and development virology division at the Pasteur Institute of strategies, as China has done. Iran in Tehran, about the nation’s vaccine landscape. Azadmanesh also advises the Why are Iranian researchers reluctant to Iranian government and is developing publicize their work internationally? vaccines through his spin-off company This could be another effect of the sanctions. Humimmune Biotech. Researchers in Iran might not want to draw too much attention to their work in case they How badly has the pandemic affected Iran? put potential partnerships in jeopardy or they Since January 2020, we’ve had five waves. run the risk of losing access to raw materials. We’re currently experiencing the highest Researchers are also extremely busy number of new cases reported so far, with during the pandemic. But some have started MAJID ASGARIPOUR/WANA VIA REUTERS MAJID ASGARIPOUR/WANA around 40,000 a day, and the most common to share results. In June, the researchers variant we detect is Delta.
    [Show full text]
  • Accelerating Vaccination Against Covid-19
    Accelerating vaccination against Covid-19 Press release of the French National Academy of Medicine April 12, 2021 The major challenge in overcoming the current health crisis is to acquire a sufficient herd immunity to control the circulation of SARS-CoV-2 and to consider the relaxation of restriction measures. Two factors contribute to this collective immunity: the proportion of people who have been infected since the beginning of the pandemic, estimated at 20% of the French population, and the vaccination coverage, which has just exceeded 18% of adults for the first injection. Post-infectious immunity is based on neutralizing antibodies that persist for more than one year after a moderate or severe form of Covid-19, and 6 to 8 months after an asymptomatic form [1], but also on the cellular response of T lymphocytes. This observation has led the French High Authority for Health to recommend that vaccination of immunocompetent individuals with confirmed SARS-CoV-2 infection be delayed for 3 to 6 months after the infectious episode and reduced to a single dose [2]. The vaccination coverage rate to reach the control of the epidemic has been increased to take into account the increased transmissibility of the B.1.1.7 variant, known as "British", which has become predominant throughout metropolitan France. According to the Pasteur Institute's modelling, more than 90% of the adult population would need to be vaccinated to achieve this objective, as long as the vaccination of children is not foreseen [3]. These estimates reinforce the prospect of a sustained circulation of SARS-CoV-2, which may lead to the emergence of new variants, with deleterious consequences on public health and the country's economy.
    [Show full text]
  • MRC Centre for Outbreak Analysis and Modelling
    Centre for Outbreak Analysis and Modelling MRC Centre for ANNUAL REPORT Outbreak Analysis and Modelling www.imperial.ac.uk/medicine/outbreaks 2012 The Centre specialises in quantitative epidemiology encompassing mathematical modelling, statistical analysis and evolutionary epidemiology, to aid the control and Director’s message treatment of infectious diseases. April 2013 sees the Centre renewed for a second 5-year Consortium (led by Tim Hallett) and the Vaccine Modelling term, after we received an unprecedented 10 out of 10 Initiative – are up for renewal. However, grants are only score from the MRC subcommittee, which assessed the one aspect of the relationship. As important are the close performance of the Centre over its first term. Just as the working relationships between staff in the Centre and the work of the Centre over that time has been very much a Foundation, which sees our research increasingly used to team effort, so was the success of the renewal. inform Foundation strategy and delivery. The last few months have seen us start to drive through Despite its title, the Centre’s mission rapidly evolved to our strategy for the next 5 years. A crucial aspect of this encompass delivering innovative epidemiological analysis is to boost capacity in key research areas. It is therefore not only of novel infectious disease outbreaks, but also of my pleasure to welcome new academic staff into the endemic diseases of major global health significance. Our Centre. Xavier Didelot joined us last year as a lecturer in work on polio, malaria and HIV reflects this. However, the pathogen genetics, and our expertise in evolutionary and last few months have highlighted the ongoing relevance of genetic research will be further boosted this year by the our original mission to enhance preparedness and response recruitment of at least one additional member of academic to emerging disease threats.
    [Show full text]
  • News in Focus FEI/NYT/REDUX/EYEVINE SLAM YIK ​ Paramedics Transport a Man Thought to Be the First Person in Hong Kong to Have Contracted the New Coronavirus
    The world this week News in focus FEI/NYT/REDUX/EYEVINE SLAM YIK Paramedics transport a man thought to be the first person in Hong Kong to have contracted the new coronavirus. WHAT SCIENTISTS WANT TO KNOW ABOUT THE CORONAVIRUS OUTBREAK Researchers have sequenced the deadly pathogen’s genome — and are now rushing to find out how it spreads and how deadly it is. By Ewen Callaway and David Cyranoski Researchers fear similarities to the 2002–03 international concern — the agency’s highest epidemic of severe acute respiratory syn- level of alarm — after a meeting of officials last he world is racing to learn more about drome (SARS), which emerged in southern week, but that could change. the outbreak of a new viral infection that China and killed 774 people in 37 countries. Nature rounds up the questions at the heart was first detected in Wuhan, China, last Both are members of a large virus family, called of scientists’ efforts to understand the virus. month and is causing increasing alarm coronaviruses, that also includes viruses around the world. responsible for the common cold. How does the virus spread? TAs Nature went to press, officials in China China has taken unprecedented action to try This is the most urgent question surrounding had confirmed more than 4,500 cases of the to halt the outbreak — including putting Wuhan the outbreak. Chinese authorities have con- virus, which causes a respiratory illness, and and nearby cities on ‘lockdown’, restricting firmed that it spreads from person to person some 100 deaths. Around 50 cases had also travel in and out of the cities.
    [Show full text]
  • Special Edition - 5Th UPDATE 05/03/21
    IMMUNOWATCH Special edition - 5Th UPDATE 05/03/21 COVID-19 INTRODUCTION MabDesign and the COVID-19 pandemic The COVID-19 pandemic was matched by an unprecedented mobilisation of the French immunotherapy network and the pharmaceutical industry at large. Indeed, at the time of publication, three French companies already have preventive and/or therapeutic candidates currently undergoing Phase III clinical trials. In parallel, several bioprocessing sites across France have secured contracts for the production of both drugs and vaccines against SARS-CoV-2. These tremendous results were made possible through accelerated R&D as well as production and distribution logistics combined with facilitated access to information, resources and potential collaborators. MabDesign has been continuously adapting its actions and services to further support and enhance this nationwide pandemic response. Our latest and ongoing contribution to the fight against COVID-19 is through this special edition of Immunowatch and its regular updates. MabDesign’s Immunowatch is a one-of-a-kind information monitoring newsletter in the field of biomedicaments which aims at providing members of our association with the most recent and relevant data gathered or generated through the key expertise of MabDesign and its collaborators in scientific research, business intelligence, market analysis and intellectual property. Its original format has been modified to cater for the fast evolution of the response to the COVID-19 pandemic and allow rapid and pertinent updates. Immunowatch is done in collaboration with the MAbMapping Unit of the Ambition Recherche & Développement (ARD) Biomédicaments 2020 Phase II programme, funded by the Centre Val de Loire region. 2 Table of content 4.
    [Show full text]
  • Vaccines to Prevent Sars-Cov-2 Infection
    CORONAVIRUS DISEASE 2019 (COVID- 19):VACCINES TO PREVENT SARS-COV-2 INFECTION Dr Amitis Ramezani Head of Clinical Research group., Pasteur Institute of Iran Overview of vaccine development • Vaccines to prevent SARS-CoV-2 infection are considered the most promising approach for curbing the pandemic and are being vigorously pursued. As of winter 2020, several vaccines have become available for use in different parts of the world, over 40 candidate vaccines were in human trials, and over 150 were in preclinical trials. • When most people in a community are vaccinated against a disease, the ability of the pathogen to spread is limited. This is called ‘herd’ or ‘indirect’ or ‘population’ immunity. • When many people have immunity, this also indirectly protects people who cannot be vaccinated, such as very young babies and those who have compromised immune systems. • As with the development of pharmaceuticals, vaccine development progresses through preclinical evaluation and three distinct clinical stages, phases I, II, and III . Traditionally, these steps occur sequentially, and each usually takes several years for completion. SARS-CoV-2 vaccine development has accelerated to an unprecedented pace, with each step occurring over several months. Nevertheless, safety criteria remain stringent. • In the United States, the Food and Drug Administration (FDA) must approve progression to each next step in human trials, from initiation of phase I trials through progression to phase III trials. Steps in vaccine development Actions taken to ensure a
    [Show full text]
  • The History of the International AIDS Society (IAS) Is Intertwined with Its Conferences, and in the Struggle for Evidence and Ex
    The history of the International AIDS Society (IAS) is intertwined with its conferences, and in the struggle for evidence and experience to prevail over ignorance and political expediency in the global response to HIV/AIDS. For an epidemic that was initially identified with stigmatized communities, and which quickly escalated in the poorest and most vulnerable populations on the globe, this was – and continues to be – an enormous challenge. Nevertheless, addressing what HIV scientist and human rights activist, Jonathan Mann referred to as “the epidemic of stigma, discrimination, blame and collective denial” has become as integral to International AIDS Conferences as the search for new and better prevention, care and treatment interventions. The IAS was founded in 1988 to be the agency responsible for planning and implementation of the rapidly-growing International AIDS Conferences at which the most current epidemiological and biomedical knowledge would be presented and debated. At the same time, it became the representative of the international scientific community and often the voice of reason in the controversies that have plagued the response to this epidemic. Before we look at the formal establishment of the IAS, it is important to recall the earliest conferences and the emerging epidemic that drove the need for an evolving global forum on one of the greatest public health challenges we face. The following episode is one of 12 to be released each month in 2013 which will chronologically cover the history of the IAS over the last 25 years. The first International AIDS Conference in Atlanta in 1985 was organized to present an overview of knowledge about this emerging epidemic, including possible aetiology, clinical progression, modes of transmission, epidemiological trends and the new test for Human Immunodeficiency Virus (HIV), recently identified as the causative agent amid much controversy between French and American scientists.
    [Show full text]
  • Pdf Ment and Disease Emergence in Humans and Wildlife
    Peer-Reviewed Journal Tracking and Analyzing Disease Trends pages 853-1040 EDITOR-IN-CHIEF D. Peter Drotman Managing Senior Editor EDITORIAL BOARD Polyxeni Potter, Atlanta, Georgia, USA Dennis Alexander, Addlestone, Surrey, UK Associate Editors Timothy Barrett, Atlanta, Georgia, USA Paul Arguin, Atlanta, Georgia, USA Barry J. Beaty, Ft. Collins, Colorado, USA Charles Ben Beard, Ft. Collins, Colorado, USA Martin J. Blaser, New York, New York, USA Ermias Belay, Atlanta, Georgia, USA Christopher Braden, Atlanta, Georgia, USA David Bell, Atlanta, Georgia, USA Arturo Casadevall, New York, New York, USA Sharon Bloom, Atlanta, GA, USA Kenneth C. Castro, Atlanta, Georgia, USA Mary Brandt, Atlanta, Georgia, USA Louisa Chapman, Atlanta, Georgia, USA Corrie Brown, Athens, Georgia, USA Thomas Cleary, Houston, Texas, USA Charles H. Calisher, Ft. Collins, Colorado, USA Vincent Deubel, Shanghai, China Michel Drancourt, Marseille, France Ed Eitzen, Washington, DC, USA Paul V. Effler, Perth, Australia Daniel Feikin, Baltimore, Maryland, USA David Freedman, Birmingham, Alabama, USA Anthony Fiore, Atlanta, Georgia, USA Peter Gerner-Smidt, Atlanta, Georgia, USA Kathleen Gensheimer, Cambridge, Massachusetts, USA Stephen Hadler, Atlanta, Georgia, USA Duane J. Gubler, Singapore Nina Marano, Atlanta, Georgia, USA Richard L. Guerrant, Charlottesville, Virginia, USA Martin I. Meltzer, Atlanta, Georgia, USA Scott Halstead, Arlington, Virginia, USA David Morens, Bethesda, Maryland, USA Katrina Hedberg, Portland, Oregon, USA J. Glenn Morris, Gainesville, Florida, USA David L. Heymann, London, UK Patrice Nordmann, Paris, France Charles King, Cleveland, Ohio, USA Tanja Popovic, Atlanta, Georgia, USA Keith Klugman, Seattle, Washington, USA Didier Raoult, Marseille, France Takeshi Kurata, Tokyo, Japan Pierre Rollin, Atlanta, Georgia, USA S.K. Lam, Kuala Lumpur, Malaysia Ronald M.
    [Show full text]
  • For Their Discovery of Human Immunodeficiency Virus
    2008 NOBEL LAUREATES The Nobel Prize in Physiology or Medicine 2008 “for his discovery of “for their discovery human papilloma of human viruses causing immunodeficiency cervical cancer” virus” ) X X I I P P DKFZ SCAN SCAN AKUTIN/ AGUNIA/ S M DEUTSCHES KREBSFORSCHUNGSZENTRUM ( KREBSFORSCHUNGSZENTRUM DEUTSCHES Harald zur Hausen Françoise Luc Montagnier 1/2 of the prize Barré-Sinoussi 1/4 of the prize 1/4 of the prize Born: 1936 Born: 1932 Birthplace: Germany Born: 1947 Birthplace: France Nationality: German citizen Birthplace: France Nationality: French citizen Current position: Nationality: French citizen Current position: Professor Emeritus and Current position: Professor Emeritus and former Chairman and Professor and Director, Director, World Foundation Scientific Director, German Regulation of Retroviral for AIDS Research and Cancer Research Centre, Infections Unit, Virology Prevention, Paris, France Heidelberg, Germany Department, Institut Pasteur, Paris, France PHYSIOLOGY OR MEDICINE 13 Copyright © Nobel Web AB 2008. Nobelprize.org, Nobel Prize and the Nobel Prize medal design mark are registered trademarks of the Nobel Foundation. 2008 NOBEL LAUREATES Speed read: Finding the culprit identification of the virus associated with AIDS, occurred within just a few months amid a flurry of global research activity directed towards finding the cause of the then-new epidemic. Harald zur Hausen’s suggestion that human papilloma virus (HPV) infection might lie behind cervical cancer flew in the face of general opinion in the early 1970s, which held that another commonly present virus, herpes simplex virus, might be the cause. Realising that there were a multitude of different HPV subtypes, and hypothesising that unknown subtypes might cause the cancer, zur Hausen’s group began a painstaking search for such novel ooking back over the two discoveries rewarded viruses.
    [Show full text]